[ad_1]
In view of the slow start of corona vaccination, critical voices against the federal government and the EU are increasing. In the SPIEGEL conversation, for example, Biontech boss Uğur Şahin criticized the European ordering strategy. “Many other companies were supposed to come with vaccines. Apparently the impression prevailed: we will have enough, it won’t be so bad and we have it under control, ”Şahin said.
The neurologist Frauke Zipp of the Leopoldina National Academy of Sciences even spoke with the newspaper “Die Welt” of “a serious failure of those responsible”. He asked why they did not order more vaccines at risk in the summer: “A short time ago official commemoration of the dead, now apparently no longer counts all the days in which human lives could be saved. Now patience is required,” continues Zipp.
The opposition in the Bundestag also adds to the criticism of the purchase of vaccines. The general secretary of the FDP, Volker Wissing, also told the “Welt”: “We can see from the example of Israel and other countries that it is possible to vaccinate more quickly. The federal government has to explain very well why things are going so slowly in Germany. “
Kordula Schulz-Asche of the Greens parliamentary group said that from today’s perspective one should have asked more than 100 developers at risk. However, the Biontech vaccine was still in the testing phase in the summer.
Left boss Bernd Riexinger sees it similarly. Therefore, the federal government should “quickly issue licenses for the post-production of the Biontech / Pfizer vaccine,” he said. That is directly in the hand of the Minister of Health, Jens Spahn (CDU). The mutation of the virus in Britain makes it clear: “A successful vaccination strategy is also a race against time.”
Bet on the wrong manufacturers
The vaccine procurement problems now felt in Germany are also related to the purchasing policy of the European Union. DER SPIEGEL reported that the EU had trusted the wrong manufacturers: the French company Sanofi and the British-Swedish manufacturer AstraZeneca. Both had to significantly postpone the approval of their vaccines.
Other vaccines approved today would also have been sufficiently available. Moderna’s boss, Stéphane Bancel, for example, told SPIEGEL that his company could have provided many more vaccines.
